-+ 0.00%
-+ 0.00%
-+ 0.00%
AlphaValue/Baader Europe Lifts Sandoz Price Target After Updated FY26 Guidance
Share
Listen to the news
07:59 AM EST, 11/17/2026 (MT Newswires) -- AlphaValue/Baader Europe increased its price target for Sandoz Group (SDZ.SW) to 89.9 francs from 84.5 francs as it took into account the Swiss drugmaker's updated guidance for full-year 2026. "Besides incorporating the 2026 guidance upgrade, we have revisited our out-year assumptions, considering 1/ the unrelenting growth of Sandoz's biosimilars (expanding at an average c.21% CER between 2022 and 9M 26) and 2/ the firm being among the few players with a competitive advantage in development, production and commercialisation of biosimilars," analysts wrote in a Tuesday note. "Not only is the biosimilar market envisioned to gallop at a nearly 20% rate over 2025-35 (backed by the upcoming patent expirations of massive multi-blockbuster biologic drugs), but they are also higher margin products than traditional generics." The research firm's adjustments to its out-year projections include an EBITDA growth rate of 6%, up from the previous estimate of 5.5%. "That said, our recommendation remains REDUCE, as stratospheric gains (+>260%) since Sandoz's public listing in October 2023 suggest that most of the favourable aspects of its growth story have been baked in by the markets," analysts said.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending